The state of Georgia currently has 29 active clinical trials seeking participants for Alzheimer's Disease research studies. These trials are conducted in various cities, including Atlanta, Augusta, Decatur and Savannah.
Improving Sleep and AD Biomarkers
Recruiting
The purpose of this research is to learn whether a dietary citicoline supplement will impact sleep and cognition. Cognitive disorders include such things as memory disorders and mild cognitive impairment. The investigators are studying persons with mild cognitive impairment (MCI). For this population, the team will assess whether citicoline also impacts biomarkers, a marker of the patient's biological state, in their body. The investigators are interested in learning more about a dietary supple... Read More
Gender:
All
Ages:
60 years and above
Trial Updated:
01/11/2024
Locations: Emory University School of Nursing, Atlanta, Georgia +1 locations
Conditions: Mild Cognitive Impairment, Alzheimer Disease
Improving Sleep and Cognition in Alzheimer's Disease
Recruiting
Cognitive disorders include such things as memory disorders, mild cognitive impairment, and Alzheimer's disease (AD). The purpose of the study is to learn more about whether a dietary citicoline supplement will improve sleep and cognition. Sleep disturbances currently afflict approximately 25-44% of those with AD, resulting in decreased quality of life for those with AD and their caregivers and are a major driver of institutionalization. Previous studies have tested this dietary supplement in A... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: Emory University School of Nursing, Atlanta, Georgia +1 locations
Conditions: Alzheimer Disease
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
Recruiting
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of MK-2214 in adults with mild cognitive impairment (MCI) or mild-to-moderate Alzheimer's Disease (AD). The primary hypothesis (Part 1) is that at a generally well tolerated dose level, the true geometric mean concentration at Day 85 of MK-2214 in cerebrospinal fluid is >0.3 nanomolar (nM). Optional healthy older participants (Part 2) may receive MK-2214 at dose levels determined by criter... Read More
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
01/03/2024
Locations: CenExel iResearch, LLC ( Site 0002), Decatur, Georgia
Conditions: Alzheimer Disease
TRC-PAD Program: In-Clinic Trial-Ready Cohort
Recruiting
The purpose of the TRC-PAD study is to develop a large, well-characterized, biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention trials utilizing the APT Webstudy and subsequent referral to in-clinic evaluation and biomarker confirmation. Participants with known biomarker status may have direct referral to the Trial-Ready Cohort. If you are interested in being selected for the TRC-PAD study, you should first enroll in the APT Webstudy (https://www.aptwebstud... Read More
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
11/30/2023
Locations: Emory University, Atlanta, Georgia +1 locations
Conditions: Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
Down Syndrome Clinical Trials - Study of Alzheimer's Disease in Down Syndrome
Recruiting
The primary objective is to characterize trajectories of change on the primary outcome measures in this study population through longitudinal collection of measures of cognition, function, behavior, and health status.
Gender:
All
Ages:
25 years and above
Trial Updated:
11/09/2023
Locations: Emory University, Atlanta, Georgia
Conditions: Alzheimer's Disease in Down Syndrome
Longitudinal Early-onset Alzheimer's Disease Study Protocol
Recruiting
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EOnonAD) participants, and (3) cognitively normal (CN) control participants.
Gender:
All
Ages:
Between 40 years and 64 years
Trial Updated:
11/06/2023
Locations: Emory University, Atlanta, Georgia
Conditions: Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
Recruiting
This is a phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to phase 2B. In phase 2A there will be adaptive dosing evaluation of three dose levels with exposure to varoglutamstat or placebo for a minimum of 24 weeks, with preliminary evaluation of both cognitive function and pharmacodynamic changes on EEG spectral analysis in approximately 180 participants. In the event that the stage gate for phase 2B is reached, the... Read More
Gender:
All
Ages:
Between 50 years and 89 years
Trial Updated:
11/01/2023
Locations: Emory University, Atlanta, Georgia
Conditions: Alzheimer Disease
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Recruiting
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
10/10/2023
Locations: Columbus Memory Center, PC, Columbus, Georgia +3 locations
Conditions: Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
A Study of Seltorexant in Participants With Probable Alzheimer's Disease
Recruiting
The purpose of this study is to investigate the effect of seltorexant versus placebo on the sum of Agitation and Aggression domain scores (A plus A) of the Neuropsychiatric Inventory-Clinician rating (NPI-C) in participants with probable Alzheimer's Disease (AD) with clinically significant agitation/aggression.
Gender:
All
Ages:
Between 55 years and 85 years
Trial Updated:
10/10/2023
Locations: Sonar Clinical Research, Atlanta, Georgia +2 locations
Conditions: Alzheimer Disease
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Recruiting
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
10/06/2023
Locations: Emory University, Atlanta, Georgia
Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
Recruiting
The purpose of this study is to investigate whether a blood pressure medication, spironolactone, can be tolerated by older African American adults that have memory and thinking problems, also called mild cognitive impairment (MCI). This study will also investigate the effect of spironolactone on memory and thinking abilities as measured by performance on cognitive tests, which are tests that measure memory and thinking skills. Participants will take spironolactone or a placebo for one year and w... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
09/21/2023
Locations: Emory Clinic at Executive Park, Atlanta, Georgia
Conditions: Mild Cognitive Impairment, Alzheimer Disease
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease
Recruiting
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. This study will assess how safe and effective ABBV-916 is in treating ea... Read More
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
07/31/2023
Locations: Columbus Memory Center /ID# 245054, Columbus, Georgia
Conditions: Alzheimer's Disease (AD)